BioCryst Pharma (BCRX) PT Lowered to $25 at Citizens After Missing 3Q Sales Consensus
Tweet Send to a Friend
Citizens analyst Jonathan Wolleben lowered the price target on BioCryst Pharma (NASDAQ: BCRX) to $25.00 (from $27.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
